Eleven Biotherapeutics (EBIO) Swings to Q3 Profit

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of $0.95, versus $0.50 reported last year. Revenue for the quarter came in at $28.7 million, versus $100 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery